Peptide Usage Statistics 2026: What 1,000+ Users Report
In May 2026, Peptime (@ItsPeptime on X) posted peptide usage statistics from a self-selected online survey of 1,000+ peptide users. The dataset is one of the largest non-clinical reads on how peptides are actually being sourced, paid for, and combined in 2026. Below: every finding rebuilt with original tables, our analysis, and the limitations to read it with.
Update History ▾
October 12, 2026: Removed content-planning and conversion language (the SEO two-layer note, the “suppliers and content creators” paragraph, the “buying cohort” framing and the “not yet conversion audience” label), described the industry and age figures as use rates rather than cohort sizes, labelled the 3.2/4 stack rating correctly on the survey’s four-point scale, fixed “paid-off car payment”, and pointed the verification link to the retatrutide supplier checklist instead of the home page.
October 7, 2026: Corrected the survey attribution. The cited X post is by Peptime (@ItsPeptime), which describes itself as a US peptide shop, not by Peptidepedia. Removed the 72% GLP-1 share, the 47% longevity share and the gender table, which do not appear in the source post. Changed “about one in five” to “fewer than one in five” to match the source.
May 19, 2026: Initial publication. All eight findings rebuilt with original tables; primary source verified against the Peptidepedia post on May 18, 2026.
Research summary
The Peptime 2026 survey describes what more than 1,000 self-selected respondents said about peptide purchasing and use; it is not a clinical study or a representative population estimate.X post
- Respondents commonly reported research-use-only-labelled sources and monthly spending, including a smaller high-spending group.
- Self-report, recruitment and community-engagement bias limit how far these results can be generalized.
The survey does not establish product safety, effectiveness, legality, or typical use in the wider population.
Summary revised November 1, 2026. This editorial update does not constitute a new literature review.
Peptide Usage Statistics at a Glance
The table below puts the survey’s headline peptide usage statistics in one place. Each figure is self-reported by people who chose to answer a peptide seller’s questionnaire. Read them as peptide statistics for engaged users. They are not population prevalence, and they do not show how many people use peptides overall. The next section covers what is known about that.
Evidence and context
The Peptime 2026 survey is not a clinical study, but at 1,000+ respondents it is one of the largest community reads on how peptides are actually being bought and used. Two structural patterns stand out. Sourcing is dominated by the gray market — 70% of respondents buy from suppliers selling under a “Research Use Only” label, and most are explicit that they know they are operating in a legal gray zone. Spending is concentrated and high — the median user reports $100–$249 a month, but roughly 11% report $1,000+ a month, which puts annual spend above $12,000. All of it is self-reported by engaged users; none of it is peer-reviewed.
Additional context
- 70% source from “Research Use Only” suppliers; only 11% go through a local doctor or telehealth provider.
- 68% describe their own use as a “legal gray area”; another 14% call it “probably illegal.”
- Median spend is $100–$249/month; 11% report $1,000+/month (≈ $12,000+/year).
- Tech has the highest reported use rate — 75%, well ahead of finance (46%) and consulting (45%).
- Stacks beat singles on self-rated effectiveness — 3.2/4 for 3+ peptide stacks vs 2.0/4 for single-peptide use.
- 25–34 reports the highest use rate — 75%, more than triple the 18–24 cohort.
- 68% rate their experience as “very effective” or “life-changing” — self-report only, no control, heavy selection bias.
| Measure | Survey result |
|---|---|
| Respondents | 1,000+ (opt-in, posted May 18, 2026) |
| Buy from “Research Use Only” suppliers | 70% |
| Median monthly spend | $100–$249 |
| Spend $1,000+ a month | 11% |
| Use rate, ages 25–34 | 75% |
| Self-rating, 3+ peptide stacks vs singles | 3.2/4 vs 2.0/4 |
| Rate their use “very effective” or better | 68% |
About the Survey
A few months before May 2026, Peptime — an X account (@ItsPeptime) that describes itself as a US peptide shop — ran an opt-in survey on its own website. Its May 18, 2026 post reported 1,000+ anonymous responses and summarised findings on sourcing channel, monthly spend, industry, age, stacking behaviour, and self-rated outcomes.
This is not a clinical study. It is a self-selected online survey of people who already had enough interest in peptides to find a peptide seller’s website and finish the questionnaire. That has predictable consequences for the data:
- Selection bias is heavy. Respondents skew toward engaged, current users.
- All outcomes are self-reported. There are no verified labs, biomarkers, or controls.
- Heavy users are likely over-represented. The casual or one-time user is under-counted.
Read with those caveats in mind, the survey is best treated as a market-state snapshot of the engaged peptide user base in 2026 — not as evidence about whether or how well any specific compound works in a general population.
How Many People Use Peptides?
We found no reliable count of how many people use peptides outside a prescription. A 2026 review of unregulated peptide use in Cureus explains the gap. Current systems may not capture who uses nonprescribed peptides, which products they use or where they get them, and the authors list measuring prevalence as the first research priority. An opt-in survey cannot fill that gap. Peptime’s 1,000+ respondents show how engaged peptide users behave. They do not show what share of any population uses peptides.
How Many People Use Peptides in the US?
The best US population figures cover prescribed GLP-1 drugs, which are peptide medicines. KFF notes they are used for weight loss and to treat diabetes, heart disease and other chronic conditions. In a nationally representative KFF poll of 1,350 adults, run October 27–November 2, 2025, 12% said they were currently taking a GLP-1 drug such as Ozempic or Wegovy, and 18% said they had taken one at some point. Gallup surveyed 5,065 adults on May 28–June 5, 2026 and found 11% currently taking GLP-1 medications for weight loss, up from 3% in 2024. In the same Gallup data, 66% of current users were on a brand-name drug and 18% on a compounded or custom-mixed version.
Neither poll was designed to measure research-label products such as BPC-157 or TB-500. For that part of the market, data on peptide users still comes from opt-in surveys like this one.
Finding 1: Grey Market Peptides Dominate — 70% of Users Source From RUO Suppliers
The clearest result in the dataset is also the most consequential. Seven in ten respondents reported buying grey market peptides — product sold under a “Research Use Only” label rather than through a prescription pathway. Fewer than one in five users went through any kind of doctor. The gray market is not a transition state in this data; it is the primary distribution channel.
Where Do People Buy Peptides?
In this survey, 70% of respondents bought from research-only suppliers, 12% used an overseas clinic, 11% a local doctor or telehealth provider and 9% friends or informal channels. Most people in this sample buy outside a prescription pathway.
Prescribed GLP-1s follow the opposite pattern. In the KFF poll, 76% of people who had taken a GLP-1 drug got it from one of their doctors, 17% from an online provider or website and 9% from a medical spa or aesthetic centre. The 2026 Cureus review lists the routes people may use to get unregulated peptides. They include direct-to-consumer websites, sellers of research chemicals, online communities, international suppliers, compounding-related pathways and wellness clinics. Our peptide supplier checklist sets out what to record about any source.
| Source channel | Share of respondents | What it means |
|---|---|---|
| “Research Use Only” supplier | 70% | Material sold for in-vitro research, not for human use |
| Overseas clinic | 12% | Prescription written abroad, product imported |
| Local doctor or telehealth | 11% | Domestic prescription pathway |
| Friends or informal channels | 9% | Unverified provenance and storage chain |
Awareness of the legal posture is high. 68% of respondents called their own use a “legal gray area,” another 14% described it as “probably illegal,” and only 18% believed what they were doing was clearly legal. The framing matters: the gray market is not a transient state on the way to regulation in this sample. It is the dominant distribution channel and users are explicit that they understand what that means. For research-grade buyers, the consequence is that supplier verification — third-party HPLC, batch COAs, cold-chain handling, and a real address — carries more weight than nominal compliance language. Our COA library exists for exactly this reason.
Finding 2: Annual Spend Reaches $12,000+
Spending is concentrated. The median respondent spent $100–$249 a month — consistent with a single GLP-1 product cycled monthly — but the top of the distribution is steep. Roughly 11% reported $1,000+ a month, which annualises to $12,000 or more per user. That puts the heavy-user cohort in territory normally reserved for private school tuition or a monthly car payment.
How Much Do Peptides Cost per Month?
The survey answers a narrower question: what users say they spend. It reports spend bands, not prices for any product, and it does not say which compounds each respondent bought. Cost is also a common complaint with prescribed GLP-1 drugs. In the KFF poll, 56% of users said the drugs were difficult to afford, and 27% of insured users paid the full cost themselves.
| Monthly spend tier | Share of respondents | Approx. annualised |
|---|---|---|
| Under $500 (all lower bands combined) | About 71% (remainder of sample) | < $6,000 |
| $100 – $249 (median band) | Median respondent; share not published | $1,200 – $3,000 |
| $500 – $999 | 18% | $6,000 – $12,000 |
| $1,000+ | 11% | $12,000+ |
The takeaway from the survey is structural: this is not a casual hobbyist category. A meaningful slice of users are spending mid-five figures a year, which has implications for how seriously suppliers need to take cold-chain integrity, batch documentation, and customer support.
Finding 3: Tech Leads Industry Adoption
The industry breakdown reads like a chart of who has both disposable income and an information-dense relationship with their own bodies. Tech sits at the top by a clear margin; healthcare and biotech follow, which suggests a domain-knowledge effect; construction lands surprisingly high, which is harder to explain from the public data alone.
| Industry | Reported use rate | Read |
|---|---|---|
| Technology | 75% | Highest reported use rate; high income, high biohacking saturation |
| Healthcare / biotech | 59% | Domain familiarity lowers the activation barrier |
| Construction | 55% | Physical-recovery use case is plausible but unverified |
| Finance | 46% | Disposable income, less category fluency |
| Consulting | 45% | Similar profile to finance |
The number to be careful with here is the construction figure. The survey reached users through Peptime’s own audience, which means the industry mix is shaped by who already reads peptide content — not by the broader workforce. A 55% use rate in a small subset of construction-industry respondents who already found a peptide site is not the same as a 55% use rate among construction workers generally.
Finding 4: Stacks Beat Singles on Self-Rated Effectiveness
Respondents using a single peptide rated their experience at 2.0/4 (“somewhat effective”). Respondents stacking three or more compounds rated theirs at 3.2/4 (between “very effective” and “life-changing”). That is a 60% jump on a self-rating scale, and it is the survey’s most actionable behavioural pattern.
Two readings are possible and both probably matter. Stack composition genuinely produces better self-perceived results — users layering, say, a GLP-1 with a recovery peptide and a sleep peptide are addressing more pain points and report a larger total effect. Or the higher self-rating is partly a commitment effect — people who have invested in a three-product stack are more invested in believing it worked. Both can be true at once. The survey can’t separate them.
Finding 5: 25–34 Reports the Highest Use Rate
The use-rate jump between the youngest and the second-youngest cohort is the largest single gap in the dataset.
| Age cohort | Reported use rate | Read |
|---|---|---|
| 18 – 24 | 22% | Lowest reported use rate |
| 25 – 34 | 75% | Largest single jump in the dataset |
The pattern is consistent with what disposable-income gating looks like in any premium consumer category. Peptides cost real money on a monthly basis, and 25–34 is the cohort where that money first becomes available.
Finding 6: 68% Rate Their Experience as “Very Effective” or Better
Self-rated outcomes are the most caveat-heavy number in the survey, and we are surfacing the caveat first: these respondents took a peptide quiz on a peptide seller’s website. They are not a representative sample of anyone, and the rating reflects how engaged users feel about their use, not what any peptide actually does in a controlled setting.
| Self-rating | Share of respondents |
|---|---|
| Life-changing | 26% |
| Very effective | 42% |
| Somewhat effective | 23% |
| Not very effective | 9% |
Roughly 68% sit at “very effective” or above. That number is real for the people answering, and it explains the high re-up rate the spending data implies. What it is not is evidence that peptides produce those outcomes in a general population, in any specific protocol, or for any specific indication. Anyone reading the survey for buying signals should weight this column the lightest of the six.
What the Data Tells Us About the 2026 Peptide Market
Two structural reads come out of the dataset, regardless of where the noise sits.
The gray market is structural, not transitional. 70% of demand is being filled by suppliers selling under a research-use label. That share is too large to be a regulatory waiting room. It is the dominant channel and it is likely to stay dominant until either the legal framework changes or a regulated equivalent reaches the same price point and convenience. For buyers, the practical consequence is that supplier choice matters more than category choice — verification, COA documentation, and handling discipline are the deciding factors at the point of purchase. See our retatrutide supplier checklist for Dubai for what that verification looks like in practice.
Respondents report using stacks more than single compounds. The 3+ peptide stack rating of 3.2/4 vs the single-peptide rating of 2.0/4 is the loudest behavioural signal in the survey, though it is self-reported and may partly reflect a commitment effect (see Finding 4).
Why Are Peptides So Popular? The 2026 Peptide Craze
The survey shows where the demand sits. Respondents aged 25–34 and those working in tech both report a 75% use rate, and stacks of three or more compounds get the highest self-ratings. How popular are peptides beyond this sample? The polls above show GLP-1 use rising fast, and press coverage through 2026 describes a peptide craze around unapproved compounds as well.
The Guardian reported in February 2026 that gray market products such as BPC-157, GHK-Cu and TB-500 had built a following among biohackers. Users on Discord and Telegram claimed they help with injury recovery, athletic performance and weight loss. The paper described peptides as close to a status symbol among Bay Area tech workers. The survey’s 75% tech use rate points the same way. Two doctors it interviewed reported a sharp rise in patients asking about injectable peptides. One said the subject rarely came up before 2023.
Who Is Promoting Peptides?
The American Medical Association said in April 2026 that interest in injectable peptides is rising as more people see them promoted online by wellness influencers for weight loss, muscle growth, recovery and anti-aging. The physician it interviewed described users ranging from high school and college students in “looksmaxxing” communities to weekend athletes and middle-aged adults. Harvard Health notes that many of these products are also marketed by wellness clinics.
The purported benefits run ahead of the evidence. Harvard Health says evidence for such benefits in people is largely absent. For BPC-157, CJC-1295 and GHK-Cu it points to only a handful of test-tube and animal studies on injury recovery and wound healing. Dr. Pieter Cohen, an associate professor of medicine at Harvard Medical School, told Harvard Health that the health claims made for peptides promoted online have not been vetted by the FDA or any expert group. The survey’s popularity figures measure interest and say nothing about potential benefits.
FDA Approved Peptide Drugs vs Unregulated Peptides
Peptides are short chains of amino acids, the building blocks of proteins. The human body makes many of its own, such as insulin and growth hormone-releasing hormone, which signals the pituitary gland to release growth hormone. Lab-made peptides are often used in medications, supplements and injectable products. Harvard Health lists hormone activity, immune function, tissue repair and digestion among the jobs peptides do. It also points out that different peptides have different functions, so their benefits cannot be judged as a group. Our beginner’s guide to peptides covers the chemistry.
Peptide-based drugs are an established part of medicine. Insulin, which helps people with diabetes control their blood sugar, is one of the most widely used. GLP-1s such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are peptide medicines approved by the US Food and Drug Administration to treat diabetes and obesity. Harvard Health notes that FDA-approved peptide medications have been studied in large clinical trials.
How Many Peptides Are FDA Approved or in Clinical Trials?
The Guardian reported in February 2026 that more than 100 FDA-approved drugs are peptide-based, including insulin and GLP-1 medicines such as Ozempic. The peer-reviewed counts we found are worldwide rather than FDA-only. A 2021 perspective in Nature Reviews Drug Discovery counted more than 80 peptide drugs on the market since insulin, for conditions including diabetes, cancer, osteoporosis, multiple sclerosis, HIV infection and chronic pain. A 2015 review in Drug Discovery Today counted about 140 peptide therapeutics in clinical trials at that time. Both figures are now dated.
Many peptides sold online sit in a different category. Harvard Health says many of the injectable peptides marketed online and by wellness clinics are experimental compounds that lack FDA approval. They are typically sold through gray market storefronts and often labelled “for research purposes only.” The Guardian described these unregulated peptides as lacking reliable safety data and quality control. It also noted that BPC-157 and TB-500 are synthetic versions of proteins that occur naturally in the body. The AMA draws the same line. The physician it interviewed said newer peptides lack the same level of evidence as insulin and GLP-1s. FDA approval brings oversight of how a medicine is manufactured and distributed, and products made without FDA oversight carry added risks around contamination and sourcing.
Regulatory agencies also treat the same molecule differently by setting. The 2026 Cureus review notes that one peptide can be an approved medicine in one context and an investigational drug in another. It can also be a compounded product under specific conditions, a prohibited substance in sport or an unapproved research chemical when sold online. Sport has the clearest rule. The World Anti-Doping Agency’s 2026 Prohibited List bans BPC-157 at all times as a non-approved substance. Its S2 class, also banned at all times, names growth hormone fragments such as AOD-9604, growth hormone releasing factors such as CJC-1295, ipamorelin and tesamorelin, and growth factors including IGF-1 and TB-500. For the rules on what US compounding pharmacies may make, including the FDA’s bulk drug substances lists and the July 2026 advisory committee review, see our FDA peptide reclassification explainer.
Public Health Concerns: Adverse Effects and Gray Market Quality
The 2026 Cureus review frames unregulated peptide use as a public health issue shaped by digital promotion and gray market access. It names product failures as the most immediate risk. That covers mislabelling, contamination, inaccurate potency, non-sterility and degraded compounds. The review also notes that a certificate of analysis may not be independent, batch-specific or enough to show sterility.
Adverse events are hard to count. Users may not tell their doctors, products may be mislabelled and voluntary reporting misses many cases. The review calls for better reporting of adverse events and for clinical research on acute harms. Harvard Health reports that some injectable peptides may trigger allergic reactions, including anaphylaxis. It also notes anecdotal reports of gastrointestinal issues, headache and fatigue. It warns about potential contaminants in gray market products, which are often made overseas.
The review says online forums and wellness communities can influence how peptides are sourced and combined. Research on forum discussions, summarised in the review, found users trading sourcing tips and harm reduction advice alongside complaints about substituted or poor-quality products. The survey’s 70% research-supplier share is a market figure. The review explains why public health researchers treat it as a risk signal too.
Limitations of a Self-Selected Online Survey
Every number in this article should be read against the same set of constraints. We are surfacing them in one place rather than burying them in footnotes.
- Self-selected sample. Respondents found Peptime’s website, opted in, and finished a quiz. They are not a representative slice of any defined population.
- Self-reported responses. No lab verification, no biomarker corroboration, no third-party check on what was actually used or for how long.
- No control group. Comparison to non-users or to placebo is not possible from the data.
- Heavy users over-represented. People who spend more time on peptide content are more likely to complete a peptide quiz. The casual or one-time user is systematically under-counted.
- A seller hosted it. Peptime describes itself on X as a US peptide shop. A survey hosted by a seller reaches that seller’s audience; a survey hosted on a general-health site would likely produce different numbers.
- Recall and framing effects. Monthly spend, stacking effectiveness, and self-rated outcomes all depend on how respondents remember and frame their own behaviour.
None of these dismiss the data. They define what it is for. The survey is a directional read on engaged-user behaviour, not a clinical or market-share study. We treat it accordingly.
A Note on Research Use Only
Remy Research products are supplied for in-vitro laboratory research only. They are not intended for human or veterinary use, diagnosis, treatment, prevention, or cure of any condition. The survey data summarised here describes how respondents reported behaving and feeling; it is not guidance to act on. See our research standards for how we document and verify product on our side.
Our Research Standards
This article summarises a third-party community survey and adds our own analysis, original tables, and limitations. The primary source — the May 18, 2026 Peptime (@ItsPeptime) post on X — was re-checked on October 7, 2026 and again on October 22, 2026. All survey figures are direct from that source and cross-checked against the post text. Context figures from KFF, Gallup, WADA and the peer-reviewed reviews were added on October 22, 2026 and are listed in the references. Read our editorial policy →
- Peptime (@ItsPeptime). (2026, May 18). 1 in 9 peptide users spend $1000+ on them each month, & more crazy stats [X post and article]. x.com/ItsPeptime/status/2056380319331438992 — primary source.
- FormBlends. (2026). 2026 State of Peptides Report. finance.yahoo.com — broader market context.
- Medscape. (2026). Gray Market Peptides: So Much Hype, So Little Data. medscape.com — clinical perspective on gray-market sourcing.
- New York Post. (2026, January 14). Inside the Peptide Gray Market. nypost.com — consumer-press read on the same phenomenon.
- Hailu KT, Abriha FN, Duguma YM, Haddad RR, Liyew T, Kasagga A. (2026, June 11). Unregulated Peptide Use in the Age of Biohacking: Digital Promotion, Gray-Market Access, and Emerging Public Health Risks. Cureus, 18(6), e110657. PMID 42437212. pmc.ncbi.nlm.nih.gov — prevalence gap, sourcing routes, product-quality and adverse-event risks.
- KFF. (2025, November 14). Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition. kff.org — US GLP-1 use, where users got the drugs, and affordability.
- Gallup. (2026, July 7; updated September 8). In U.S., GLP-1 Usage Reaches New High. news.gallup.com — 2026 GLP-1 use; brand-name vs compounded share.
- Harvard Health Publishing. (2026, July 7). Peptides: What they are, potential benefits, and safety concerns. health.harvard.edu — definition, FDA status, evidence and safety.
- American Medical Association. (2026, April 29). What doctors want patients to know about injectable peptides. ama-assn.org — who is using peptides and why FDA oversight matters.
- The Guardian. (2026, February 5). ‘People are turning themselves into lab rats’: the injectable peptides craze sweeping the US. theguardian.com — press context on demand and sourcing.
- Muttenthaler M, King GF, Adams DJ, Alewood PF. (2021). Trends in peptide drug discovery. Nature Reviews Drug Discovery, 20(4), 309–325. PMID 33536635. pubmed.ncbi.nlm.nih.gov — more than 80 marketed peptide drugs.
- Fosgerau K, Hoffmann T. (2015). Peptide therapeutics: current status and future directions. Drug Discovery Today, 20(1), 122–128. PMID 25450771. pubmed.ncbi.nlm.nih.gov — about 140 peptide therapeutics in clinical trials.
- World Anti-Doping Agency. (2025, September). International Standard: Prohibited List 2026. wada-ama.org — BPC-157 under S0; peptide hormones and growth factors under S2.
Methodology disclaimer: This article summarises publicly shared findings from an independent, self-reported online survey. Numbers reflect selection bias (engaged users), self-report effects, and a single seller-hosted audience. They are not peer-reviewed clinical data and should not be read as evidence of clinical effect.